Douglas D. Leipold

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Jagath R. Junutula, Helga Raab, Suzanna Clark et al. · Nature Biotechnology · 2008 · 1.4K citations

Pharmacy, Pharmaceutics, Pharmacology +16

Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> Activity

Thomas H. Pillow, Pragya Adhikari, Robert A. Blake et al. · ChemMedChem · 2019 · 196 citations

Pharmacy, Medicinal Chemistry, Oncology +17

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold et al. · Molecular Cancer Therapeutics · 2012 · 195 citations

Medicine, Oncology, Pharmacology +17

Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry

Keyang Xu, Luna Liu, Ola M. Saad et al. · Analytical Biochemistry · 2011 · 191 citations

Pharmacy, Pharmaceutics, Pharmacokinetics +12

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

Nelson L. ‘Shasha’ Jumbe, Douglas D. Leipold, Lisa Crocker et al. · Journal of Pharmacokinetics and Pharmacodynamics · 2010 · 119 citations

Pharmacy, Oncology, Pharmacology +12